
    
      This is a Phase 2, multi-center, open-label study. Up to sixty subjects with irritable bowel
      syndrome with constipation who are between the ages of 18 and 65, inclusive, will be
      enrolled. Subjects must have completed the previous SB-2-010-001 study. The entire duration
      of the study may be up to 57 days (from enrollment to the post end-of-study [EOS] visit
      telephone call).
    
  